RE: 3 months left in H1 20243 Apr 2024 12:13
Well, we shouldn't ignore the fact that SNG001 is a drug that will potentially form part of a future pandemic response, if it is approved for use. And that makes it a potentially valuable asset for UK Gov, in a way that other drugs (e.g. those for everyday gastric ailments) are not. Have you seen how much money they are ploughing into pandemic preparedness in collaboration with our friends at AZ? : https://www.gov.uk/government/news/astrazeneca-plans-650-million-investment-in-uk
Not to say that there is any link for SNG to that, but it's a timely reminder of what's at stake. If you have a drug that answers a call by UK Gov, I think you may have a different (elevated) niche status in their psyche? In their position, I wouldn't let potential slip away, I would do all within my power to protect it. I would want it to succeed. Of course it would need to be part of the 100 day response pillar (part of UK Gov;s's pandemic preparedness strategy), so likely to be swept up under the wing of a BP that can deliver under global pandemic pressure? If any of this is in play, 'partnership' may be more of a guess than a buy-out? Who knows.... As for Universal, it could be that the data was so tantalising they wanted more, finer detailed and longer study data?